Affinage

PSMB10

Proteasome subunit beta type-10 · UniProt P40306

Length
273 aa
Mass
28.9 kDa
Annotated
2026-06-10
32 papers in source corpus 20 papers cited in narrative 20 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/7 claims corpus-supported (86%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PSMB10 (MECL-1/LMP10/beta2i) is an IFN-gamma-inducible catalytic beta subunit of the immunoproteasome that substitutes for the constitutive subunit Z/MC14 and confers the trypsin-like proteolytic activity of the assembled complex (PMID:8786291, PMID:10413086). Its incorporation into 20S proteasome precursors is reciprocally coupled to LMP2, such that each subunit's assembly depends on co-expression of the other (PMID:9256419), and PSMB10 itself is autocatalytically processed during maturation (PMID:10413086). Crystallographic analysis localizes its catalytic specificity to a distinct S1 substrate-binding pocket that differs from the constitutive beta2 subunit (PMID:30657666). Functionally, the immunoproteasome containing PSMB10 enhances generation of MHC class I antigen precursors and antigen presentation (PMID:10878350), and PSMB10 is preferentially expressed in lymphoid tissues including thymic epithelium (PMID:9174609, PMID:39734035). Beyond antigen processing, PSMB10 governs T cell proliferation and cytokine production together with LMP7 (PMID:16547243, PMID:22398747), and shapes inflammatory and fibrotic signaling by promoting IkBa/NF-kB activation, PTEN-AKT signaling, and TGF-beta-Smad2/3 output in cardiovascular and retinal disease models (PMID:29507100, PMID:29499566, PMID:28478040, PMID:33195259). It additionally regulates mitochondrial fusion by suppressing Parkin-mediated degradation of mitofusins (PMID:37501008) and modulates autophagy-dependent receptor turnover (PMID:32581853). Dominant-negative PSMB10 variants that disrupt immunoproteasome assembly and the partner subunit PSMB9 cause combined immunodeficiency through impaired thymic T cell selection (PMID:39734035, PMID:42170594, PMID:41971628).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 1996 High

    Establishing that PSMB10 is the third IFN-gamma-inducible catalytic subunit defined the molecular composition of the immunoproteasome and placed PSMB10 at its catalytic core alongside LMP2 and LMP7.

    Evidence 2D gel electrophoresis of proteasome subunits and Northern blot of IFN-gamma-treated cells

    PMID:8786291

    Open questions at the time
    • Did not resolve assembly order or interdependence with other inducible subunits
    • Catalytic activity contribution not yet assigned
  2. 1997 High

    Demonstrating reciprocal co-incorporation dependency between MECL-1 and LMP2 at the precursor stage revealed that immunoproteasome assembly is a cooperative, ordered process rather than independent subunit swapping, and that PSMB10 replaces the constitutive Z subunit.

    Evidence Cotransfection and immunoprecipitation of proteasome complexes with precursor assembly analysis

    PMID:9256419

    Open questions at the time
    • Structural basis of the dependency not defined
    • Did not address how LMP7 fits into the assembly hierarchy
  3. 1997 Medium

    Mapping reciprocal expression of MECL-1 versus constitutive MC14 across tissues established that immunoproteasome content is set at the tissue level, concentrating PSMB10 function in lymphoid organs.

    Evidence Northern blot of mouse tissues and purification of 20S proteasomes from liver, thymus, and lung

    PMID:9174609

    Open questions at the time
    • Cell-type-resolved expression within tissues not determined
    • Functional consequence of tissue-specific composition not tested
  4. 1999 High

    Active-site mutagenesis showing autocatalytic processing and assigning trypsin-like activity to the MC14/MECL-1 site defined the specific proteolytic contribution of PSMB10 to the proteasome.

    Evidence Active-site mutagenesis with stable cell lines and proteasome activity assays

    PMID:10413086

    Open questions at the time
    • Substrate repertoire of trypsin-like activity not enumerated
    • Catalytically inactive mutant still incorporated, leaving role of catalysis in assembly unresolved
  5. 2000 High

    Reconstituting full immunoproteasomes and showing enhanced epitope precursor generation connected PSMB10-containing complexes mechanistically to improved MHC class I antigen presentation.

    Evidence Triple transfection with in vitro degradation assays and cell-based antigen presentation

    PMID:10878350

    Open questions at the time
    • PSMB10-specific contribution not separable from LMP2/LMP7 in the triple transfectant
    • Generality across diverse epitopes not established
  6. 2006 Medium

    Double-knockout T cell hyperproliferation revealed an immunoproteasome function in controlling T cell cycling that is independent of antigen processing, requiring combined loss of MECL-1 and LMP7.

    Evidence LMP7/MECL-1 double-knockout mice with mitogen stimulation and cell cycle analysis

    PMID:16547243

    Open questions at the time
    • Molecular substrate controlling proliferation not identified
    • Single-subunit contribution masked by epistasis
  7. 2012 Medium

    Defining a specific subset of cytokines regulated by LMP7/MECL-1 distinguished immunoproteasome-dependent from proteasome-general control of T cell effector programs.

    Evidence Double-knockout splenocytes with PMA/ionomycin stimulation and qRT-PCR

    PMID:22398747

    Open questions at the time
    • mRNA-only readout without protein-level or mechanistic dissection
    • Direct substrates linking PSMB10 to GATA3/t-bet not identified
  8. 2011 Medium

    Identifying direct E1A binding to MECL-1 and IFN-gamma-induced downregulation via STAT1 revealed that viruses target PSMB10 directly to suppress immunoproteasome formation.

    Evidence Co-IP with binding domain mapping and STAT1 phosphorylation assays

    PMID:22018786

    Open questions at the time
    • Functional consequence of E1A-MECL-1 binding for antigen presentation not quantified
    • Single lab, single viral protein
  9. 2019 High

    Co-crystal structures of beta2i-humanized proteasomes resolved the S1 pocket differences between beta2i and beta2c, providing the structural basis for the trypsin-like specificity and selective inhibitor design.

    Evidence X-ray crystallography with activity-based profiling, yeast mutagenesis, and IC50 measurement of selective inhibitor LU-002i

    PMID:30657666

    Open questions at the time
    • Human full-length immunoproteasome structure with native beta2i not solved
    • In vivo selectivity of inhibitors not addressed here
  10. 2019 Medium

    Demonstrating direct PSMB10 interaction with and degradation of CSFV NS3 extended PSMB10 function to direct antiviral restriction beyond antigen processing.

    Evidence Yeast two-hybrid, Co-IP, GST pulldown, confocal microscopy, and viral replication assays

    PMID:31493657

    Open questions at the time
    • Whether degradation requires immunoproteasome assembly versus free PSMB10 not resolved
    • Single virus, single lab
  11. 2018 Medium

    Loss- and gain-of-function studies in hypertension models defined a PSMB10-driven PTEN degradation/AKT-IKK-NF-kB and TGF-beta-Smad axis driving fibrosis and inflammation in cardiac and retinal tissue.

    Evidence PSMB10 KO and rAAV overexpression mice in Ang II and DOCA/salt models with IKKb inhibitor and pathway Western blots

    PMID:28478040 PMID:29499566 PMID:29507100

    Open questions at the time
    • Direct proteolytic versus indirect regulation of PTEN/IkBa not biochemically separated
    • All from related model systems and single lab
  12. 2020 Medium

    Tissue- and cell-specific studies extended PSMB10's NF-kB and degradation roles to autophagy-dependent receptor turnover in hypertrophy and to macrophage-intrinsic M1 polarization in atherosclerosis.

    Evidence LMP10 KO mice with in vitro knockdown, chloroquine autophagy inhibition, and myeloid-specific deletion by bone marrow transplantation

    PMID:32581853 PMID:33195259

    Open questions at the time
    • Mechanism by which PSMB10 represses autophagy not defined
    • Direct substrates (IGF1R, gp130) versus indirect effects not biochemically established
  13. 2023 Medium

    Linking beta2i to suppression of Parkin and preservation of mitofusins revealed a role in maintaining mitochondrial fusion and protecting against ischemia-reperfusion injury.

    Evidence Beta2i KO and rAAV overexpression mice in cardiac I/R with mitochondrial morphology and Parkin/Mfn1/2/Drp1 Western blots

    PMID:37501008

    Open questions at the time
    • Whether PSMB10 controls Parkin directly through proteolysis not shown
    • Single lab
  14. 2024 Medium

    Identifying a dominant-negative PSMB10 variant that collapses immunoproteasome expression and disrupts thymic T cell selection established PSMB10 as a cause of human immunodeficiency and confirmed its thymic epithelial expression.

    Evidence Patient immunophenotyping, immunoblotting, artificial thymic organoids, and single-cell RNA sequencing of human thymus

    PMID:39734035

    Open questions at the time
    • Structural mechanism of dominant-negative interference not fully resolved
    • Single patient/variant
  15. 2025 Medium

    Additional de novo dominant-negative variants showing poor proteasome integration and interference with PSMB9 consolidated PSMB10 deficiency as a combined immune deficiency caused by failed immunoproteasome assembly.

    Evidence Whole exome sequencing, proteasome assembly assays, molecular modeling, and patient-cell functional studies

    PMID:41971628 PMID:42170594

    Open questions at the time
    • Quantitative structural basis of dominant-negative effect on PSMB9 not fully defined
    • Liver disease mechanism unexplained
  16. 2025 Medium

    Demonstrating that PSMB10 knockdown enhances drug-induced senescence and limits MHC-I degradation in AML positioned PSMB10 as a modulator of chemosensitivity and immune escape in cancer.

    Evidence siRNA/lentiviral knockdown, Co-IP, polysome profiling, proteomics, and xenograft/syngeneic mouse models

    PMID:40462177

    Open questions at the time
    • Direct PSMB10 substrates in the RPL6/RPS6-MDM2-P21 axis not mapped
    • Single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved which of PSMB10's non-antigen-processing roles (NF-kB, PTEN/AKT, Parkin, autophagy) reflect direct proteolytic substrates of its trypsin-like site versus indirect consequences of altered proteasome composition.
  • No direct in vitro proteolysis of proposed regulatory substrates (PTEN, IkBa, Parkin) by reconstituted immunoproteasome
  • Free versus assembled PSMB10 contributions not separated across disease contexts

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016787 hydrolase activity 2 GO:0140096 catalytic activity, acting on a protein 2
Localization
GO:0005829 cytosol 2 GO:0005634 nucleus 1
Pathway
R-HSA-392499 Metabolism of proteins 3 R-HSA-162582 Signal Transduction 2 R-HSA-168256 Immune System 2
Partners
CSFV NS3E1APARKINPSMB8PSMB9PTEN
Complex memberships
20S proteasomeimmunoproteasome

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1997 MECL-1 (PSMB10) incorporation into the 20S proteasome is directly dependent on LMP2 expression, and conversely, LMP2 incorporation is strongly enhanced by MECL-1 expression. MECL-1 replaces the constitutive subunit Z upon incorporation. This obligatory co-incorporation occurs at the level of proteasome precursor formation. Cotransfection experiments, immunoprecipitation of proteasome complexes, analysis of precursor assembly Proceedings of the National Academy of Sciences of the United States of America High 9256419
1996 MECL-1 (LMP10/PSMB10) is the third IFN-gamma-inducible proteasome beta subunit; its transcription is increased by IFN-gamma, and it is incorporated into proteasomes while reducing incorporation of constitutive subunits (LMP-9, LMP-17, LMP-19). Together with LMP2 and LMP7, it constitutes the catalytic sites of the immunoproteasome. 2D gel electrophoresis of proteasome-associated proteins, Northern blot analysis of IFN-gamma-treated cells Journal of immunology (Baltimore, Md. : 1950) High 8786291
1997 MECL-1 (PSMB10) mRNA is predominantly expressed in thymus, lymph nodes, and spleen (lymphoid tissues), with reciprocal expression to its constitutive counterpart MC14 — tissues with high MECL-1 have low MC14 and vice versa. This reciprocal pattern was reflected in the subunit protein composition of purified 20S proteasomes from liver, thymus, and lung. Northern blot analysis of mouse tissues, purification and analysis of 20S proteasomes from liver, thymus, and lung European journal of immunology Medium 9174609
1999 MECL-1 (PSMB10) is autocatalytically processed: a catalytically inactive mutant MECL-1 was incorporated into proteasomes but showed incomplete prosequence removal. The MC14/MECL-1 active sites are specifically responsible for proteasomal trypsin-like activity, with no effect on other catalytic activities upon their loss. Mutagenesis of the active site, stable cell line expression, functional proteasome activity assays FEBS letters High 10413086
2000 Overexpression of all three inducible subunits (LMP2, LMP7, MECL-1) together in triple transfectants markedly enhanced MHC class I presentation of the LCMV NP118 epitope. In vitro, immunoproteasomes generated higher amounts of 11- and 12-mer precursor fragments containing the NP118 epitope compared to constitutive proteasomes. Triple transfection to form immunoproteasomes, in vitro proteasome degradation assays, MHC class I antigen presentation assays Journal of immunology (Baltimore, Md. : 1950) High 10878350
2006 T cells lacking both MECL-1 (PSMB10) and LMP7 (but not cells lacking only one subunit) hyperproliferate in response to polyclonal mitogens, with accelerated cell cycling in both CD4+ and CD8+ T cells. This demonstrates an immunoproteasome-specific role in T cell proliferation independent of MHC class I antigen processing. Double knockout mouse model, in vitro mitogen stimulation, cell proliferation and cell cycle analysis, flow cytometry Journal of immunology (Baltimore, Md. : 1950) Medium 16547243
2011 Adenovirus E1A directly interacts with the immunoproteasome subunit MECL-1 (PSMB10), but binds poorly to the constitutive beta2 subunit it replaces. Binding sites on E1A for MECL-1 map to the N-terminal region and conserved region 3. E1A causes downregulation of MECL-1 expression (as well as LMP2 and LMP7) induced by IFN-gamma, acting via reduction of IFN-gamma-stimulated STAT1 phosphorylation. Co-immunoprecipitation, binding domain mapping, Western blot analysis of expression levels, STAT1 phosphorylation assays Virology Medium 22018786
2012 LMP7 and MECL-1 (PSMB10) together regulate cytokine expression including IFN-gamma, IL-4, IL-10, IL-2Rb, GATA3, and t-bet in activated splenocytes, while regulation of IL-2, IL-13, TNF-alpha, and IL-2Ra by the proteasome occurs independently of these subunits. LMP7/MECL1 double-knockout mouse splenocytes, PMA/ionomycin stimulation, quantitative RT-PCR for cytokine mRNA Pharmacology Medium 22398747
2018 PSMB10 (LMP10/beta2i) promotes Ang II-induced atrial fibrillation by degrading PTEN and activating AKT1, which activates TGF-beta-Smad2/3 (leading to cardiac fibrosis) and IKKbeta-mediated ubiquitin-dependent IkBa degradation (leading to NF-kB activation and upregulation of IL-1b, IL-6, NOX2, NOX4, and CX43). PSMB10 trypsin-like activity was increased in atrial tissue and serum. PSMB10 knockout mice and rAAV9-PSMB10 overexpression mice, Ang II infusion model, IKKb inhibitor treatment, Western blot for pathway components, reactive oxygen species measurement, histological analysis Hypertension (Dallas, Tex. : 1979) Medium 29507100
2018 LMP10 (PSMB10) upregulation in retina promotes PTEN degradation and activation of AKT/IKK signaling, leading to IkBa phosphorylation and degradation and NF-kB target gene activation in Ang II-induced retinopathy. LMP10 KO mice, rAAV2-LMP10 intravitreal injection, IKKb inhibitor treatment, Western blot for signaling pathway components, pathological staining Redox biology Medium 29499566
2017 Beta2i (PSMB10) knockout ameliorates DOCA/salt-induced cardiac fibrosis and inflammation by inhibiting IkBa/NF-kB and TGF-beta1/Smad2/3 signaling pathways. Beta2i knockout mice, DOCA/salt hypertension model, echocardiography, histological staining, Western blot, qRT-PCR Biochemical and biophysical research communications Medium 28478040
2019 PSMB10 directly interacts with CSFV NS3 protein and degrades it through the ubiquitin-proteasome system, inhibiting viral replication. PSMB10 also restores MHC class I antigen presentation function suppressed by CSFV. Yeast two-hybrid screening, co-immunoprecipitation, GST pulldown, laser confocal microscopy, overexpression/knockdown experiments, viral replication assays Virology Medium 31493657
2019 Crystal structures of beta2i (PSMB10/MECL-1)-humanized yeast proteasomes with selective inhibitors revealed significant structural differences in the S1 substrate-binding pocket between beta2c and beta2i subunits, enabling rational design of selective inhibitors (LU-002i with IC50 220 nM for beta2i, 45-fold selectivity over beta2c). X-ray crystallography (co-crystal structures), organic synthesis, activity-based protein profiling, yeast mutagenesis, enzymatic IC50 measurements Journal of medicinal chemistry High 30657666
2020 LMP10 (PSMB10) knockout attenuates Ang II-induced cardiac hypertrophic remodeling via autophagy-dependent degradation of IGF1R and gp130, thereby reducing AKT/mTOR/STAT3/ERK1/2 signaling. In vitro, LMP10 knockdown activated autophagy and increased degradation of IGF1R and gp130; inhibiting autophagy with chloroquine reversed the protective effect. LMP10 KO mice, Ang II infusion, in vitro cardiomyocyte LMP10 knockdown, chloroquine autophagy inhibition, LC3II/I ratio measurement, Western blot for pathway components Frontiers in physiology Medium 32581853
2020 Myeloid-specific LMP10 deficiency (via bone marrow transplantation) attenuated atherosclerosis and reduced macrophage polarization toward M1 phenotype by decreasing IkBa degradation and NF-kB activation, demonstrating a macrophage-intrinsic role for PSMB10 in NF-kB-mediated inflammation. LMP10 KO mice, ApoE KO atherosclerosis model, bone marrow transplantation for myeloid-specific deletion, in vitro macrophage ox-LDL stimulation, Western blot, flow cytometry Frontiers in cell and developmental biology Medium 33195259
2023 Beta2i (PSMB10) expression in cardiomyocytes suppresses the E3 ubiquitin ligase Parkin, thereby preventing degradation of mitofusin 1/2 (Mfn1/2) and maintaining mitochondrial fusion. Loss of beta2i increases Parkin expression, promotes Mfn1/2 degradation, and causes excessive mitochondrial fission leading to enhanced I/R injury. Beta2i KO mice, rAAV9-beta2i overexpression, cardiac I/R model, Western blot for Parkin/Mfn1/Mfn2/Drp1, mitochondrial morphology analysis, cardiac function assessment Cellular and molecular life sciences : CMLS Medium 37501008
2024 A heterozygous PSMB10 G201R variant acts in a dominant-negative fashion to markedly reduce immunoproteasome protein expression (PSMB9 and PSMB10) in PBMCs, EBV-transformed B cells, and fibroblasts, leading to impaired positive selection of CD8 T cells, impaired generation of diverse T cell repertoire, and impaired negative selection of autoreactive T cells. PSMB10 is expressed in cortical and medullary thymic epithelial cells (confirmed by single-cell RNA sequencing of human thymus). Patient immunophenotyping, flow cytometry, immunoblotting, T-cell development in artificial thymic organoids, single-cell RNA sequencing of human thymus The Journal of allergy and clinical immunology Medium 39734035
2025 De novo dominant-negative PSMB10 variants (p.Asp205Ala and p.Ser208Phe) show poor integration into the proteasome complex and exert a dominant-negative effect on the PSMB9 subunit, leading to combined immune deficiency and liver disease. Whole exome sequencing, protein expression analysis of proteasome complex assembly, clinical immunophenotyping Journal of human immunity Medium 42170594
2025 A de novo dominant-negative PSMB10 p.G209R mutation impairs immunoproteasome assembly and function (confirmed by molecular modeling and biochemical studies), leading to defective viral sensing and antigen presentation signatures in IFN-treated fibroblasts. Molecular modeling, proteomics, transcriptomics, biochemical proteasome assembly assays, ex vivo T lymphopoiesis, Western blot Journal of human immunity Medium 41971628
2025 PSMB10 knockdown in AML cells boosts SLC22A16-mediated drug endocytosis and induces chemotherapy drug-mediated senescence through the RPL6/RPS6-MDM2-P21 pathway, while also preventing MHC-I protein degradation and thereby reducing escape from cytotoxic T lymphocyte killing. siRNA knockdown, lentivirus transduction, co-immunoprecipitation, luciferase reporter assays, polysome profiling, quantitative proteomics, xenograft and syngeneic bone marrow transplantation mouse models, flow cytometry Journal of experimental & clinical cancer research : CR Medium 40462177

Source papers

Stage 0 corpus · 32 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1997 The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proceedings of the National Academy of Sciences of the United States of America 171 9256419
1996 Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. Journal of immunology (Baltimore, Md. : 1950) 148 8786291
2000 Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. Journal of immunology (Baltimore, Md. : 1950) 96 10878350
2018 Novel Role for the Immunoproteasome Subunit PSMB10 in Angiotensin II-Induced Atrial Fibrillation in Mice. Hypertension (Dallas, Tex. : 1979) 90 29507100
2006 T cells lacking immunoproteasome subunits MECL-1 and LMP7 hyperproliferate in response to polyclonal mitogens. Journal of immunology (Baltimore, Md. : 1950) 66 16547243
1997 Molecular cloning of the mouse proteasome subunits MC14 and MECL-1: reciprocally regulated tissue expression of interferon-gamma-modulated proteasome subunits. European journal of immunology 49 9174609
2017 Knockout of immunoproteasome subunit β2i ameliorates cardiac fibrosis and inflammation in DOCA/Salt hypertensive mice. Biochemical and biophysical research communications 34 28478040
2018 The immunoproteasome subunit LMP10 mediates angiotensin II-induced retinopathy in mice. Redox biology 33 29499566
2004 Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions. International journal of oncology 32 15547699
2019 Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits. Journal of medicinal chemistry 29 30657666
1999 Mutational analysis of subunit i beta2 (MECL-1) demonstrates conservation of cleavage specificity between yeast and mammalian proteasomes. FEBS letters 23 10413086
2014 Correlation of LMP10 expression and clinical outcome in Human Papillomavirus (HPV) positive and HPV-Negative tonsillar and base of tongue cancer. PloS one 19 24752327
2023 The immunoproteasome subunit β2i ameliorates myocardial ischemia/reperfusion injury by regulating Parkin-Mfn1/2-mediated mitochondrial fusion. Cellular and molecular life sciences : CMLS 16 37501008
2021 The Immunoproteasome Subunits LMP2, LMP7 and MECL-1 Are Crucial Along the Induction of Cerebral Toxoplasmosis. Frontiers in immunology 16 33968021
2020 Deficiency of LMP10 Attenuates Diet-Induced Atherosclerosis by Inhibiting Macrophage Polarization and Inflammation in Apolipoprotein E Deficient Mice. Frontiers in cell and developmental biology 16 33195259
2011 Adenovirus E1A interacts directly with, and regulates the level of expression of, the immunoproteasome component MECL1. Virology 16 22018786
1997 DNA sequence, chromosomal localization, and tissue expression of the mouse proteasome subunit lmp10 (Psmb10) gene. Genomics 16 9367687
2012 A critical role for the inducible proteasomal subunits LMP7 and MECL1 in cytokine production by activated murine splenocytes. Pharmacology 14 22398747
2020 Deficiency of the Immunoproteasome LMP10 Subunit Attenuates Angiotensin II-Induced Cardiac Hypertrophic Remodeling via Autophagic Degradation of gp130 and IGF1R. Frontiers in physiology 11 32581853
2009 Dichotomous haplotypic lineages of the immunoproteasome subunit genes, PSMB8 and PSMB10, in the MHC class I region of a Teleost Medaka, Oryzias latipes. Molecular biology and evolution 11 19126869
2002 Identification of functional segments within the beta2I-domain of integrin alphaMbeta2. The Journal of biological chemistry 10 12324470
2018 Anti-viral immune response in the lung and thymus: Molecular characterization and expression analysis of immunoproteasome subunits LMP2, LMP7 and MECL-1 in pigs. Biochemical and biophysical research communications 9 29856997
2004 Dual function for a unique site within the beta2I domain of integrin alphaMbeta2. The Journal of biological chemistry 9 15615722
2002 Expression and regulation of interferon gamma-inducible proteasomal subunits LMP7 and LMP10 in the bovine corpus luteum. Biology of reproduction 9 12606494
2019 Host cell protein PSMB10 interacts with viral NS3 protein and inhibits the growth of classical swine fever virus. Virology 7 31493657
2013 Anti-viral immune responses in a primitive lung: characterization and expression analysis of interferon-inducible immunoproteasome subunits LMP2, LMP7 and MECL-1 in a sarcopterygian fish, the Nigerian spotted lungfish (Protopterus dolloi). Developmental and comparative immunology 6 23932981
2024 Thymic and T-cell intrinsic critical roles associated with severe combined immunodeficiency and Omenn syndrome due to a heterozygous variant (G201R) in PSMB10. The Journal of allergy and clinical immunology 5 39734035
2025 PSMB10 maintains the stemness of chemotherapeutic drug-resistant leukemia cells by inhibiting senescence and cytotoxic T lymphocyte-mediated killing in a ubiquitinated degradation manner. Journal of experimental & clinical cancer research : CR 4 40462177
2006 Genomic organization, localization and polymorphism of porcine PSMB10, a gene encoding the third beta-type proteasome subunit of 26S proteasome complex. Journal of animal breeding and genetics = Zeitschrift fur Tierzuchtung und Zuchtungsbiologie 4 16965406
2007 Molecular characterization, expression and mapping of porcine LMP2 and MECL-1 genes. DNA sequence : the journal of DNA sequencing and mapping 2 17541830
2026 Dominant-negative PSMB10 disrupts immunoproteasome assembly and leads to transient T lymphopenia. Journal of human immunity 0 41971628
2025 Novel de novo dominant PSMB10 variants in three patients with immune deficiency and liver disease. Journal of human immunity 0 42170594

Missed literature

Know a paper Affinage missed for PSMB10? Flag it for the maintainers and the community.

No submissions yet.